Selecting a CRO for PDC development should be based on five non-negotiable capabilities: peptide engineering, linker technology, payload development, conjugation chemistry, and integrated analytical/manufacturing support. The optimal partner is not one that excels in peptide synthesis alone, but one that offers end-to-end integration because PDC success hinges on the seamless interplay of all components.
A partner with proven experience in your specific payload class, such as cytotoxic or radionuclide payloads, and your linker type, such as cleavable or non-cleavable linkers, can reduce development timelines and avoid common development risks such as poor conjugation efficiency and heterogeneous product quality.
Why PDC Development Is More Challenging?
PDCs are not simply peptides with a drug attached; they are multi-component therapeutic systems where the peptide, linker, and payload must be optimised simultaneously. Any change in peptide sequence, linker stability, conjugation strategy, or payload selection can dramatically alter efficacy, PK, safety, and manufacturability.
Therefore, development requires multidisciplinary expertise across medicinal chemistry, peptide science, process chemistry, analytical development, and bioconjugation. A fragmented approach, with peptide from one vendor, linker from another, and conjugation at a third, can increase technology transfer failures and regulatory delays.
What are the five critical capabilities to evaluate in a PDC CRO?
How should you assess peptide design and optimisation expertise?
The peptide is the targeting engine. It must exhibit high affinity, stability, and favourable PK. Your CRO must demonstrate proven capabilities in sequence optimisation, cyclic peptide development, and modification strategies such as cyclisation, PEGylation, or fatty acid conjugation. Ask for case studies of peptides they have successfully translated from discovery to GMP. A partner that offers in-silico modelling alongside wet-lab synthesis is preferred, as this reduces the number of screening rounds.
What linker capabilities are non-negotiable?
The linker dictates both circulation stability and on-target release. Your CRO should have experience with multiple linker classes, including enzyme-cleavable, pH-sensitive, disulfide-based, and specialised traceless linkers. Crucially, they must be able to characterise linker stability in relevant biological matrices such as plasma and tissue homogenates and provide data on premature release. Demand to see their linker optimisation workflow and failure-mode analysis.
What payload capabilities should you require?
Payload is the warhead, and its properties, including hydrophobicity, charge, and potency, must be balanced with peptide and linker. Your CRO should offer payload synthesis, route scouting, scale-up, and impurity profiling under GMP. Crucially, they must have experience with your payload class. If you use a radiopharmaceutical payload, they need radiochemistry expertise; for cytotoxic payloads, they need high-containment capabilities. Ask for their supply chain reliability and whether they maintain a payload inventory or have access to key building blocks.
Why is conjugation expertise the most critical differentiator?
Conjugation is where many programs fail. The process must achieve high efficiency, product homogeneity, and preserved bioactivity simultaneously. Your CRO should offer multiple conjugation chemistries, including maleimide-thiol, amide coupling, click chemistry, and enzymatic approaches, and demonstrate DoE-based optimisation of reaction parameters. Most importantly, they must have analytical methods such as LC-MS and SEC to characterise conjugation sites, drug-to-peptide ratio (DPR), and aggregation. Without these, you cannot file an IND.
What analytical capabilities are essential for PDC QC?
PDC analytics go far beyond standard peptide QC. Your CRO must provide orthogonal methods for identity, purity, related substances, aggregation, payload loading, and stability-indicating assays. Essential techniques include LC-MS/MS for structural confirmation, SEC-MALS for aggregation, HPLC-UV/MS for DPR and free payload, and bioassays for potency. Crucially, they should have ICH-compliant method validation experience, which is a major area for regulatory queries. Insist on seeing their method development and validation templates.
How do integrated capabilities compare against fragmented approaches?
Most PDC programs fail due to misalignment between peptide, linker, and conjugation vendors. The table below contrasts fragmented and integrated development models across critical success factors:
| Aspect | Fragmented (Multi-CRO) Model | Integrated (Single-CRO) Model | Impact on Program |
|---|---|---|---|
| Technology transfer | Multiple handoffs — each introduces risk of batch failure and data loss | Single, seamless process under one quality system | Reduces tech transfer failures by >60% |
| Timeline | 18–24 months due to coordination delays | 12–15 months with parallel development | Saves 6–9 months to IND |
| Data consistency | Different methods, different formats — reconciliation nightmare | Uniform SOPs, single data repository | Cleaner regulatory package |
| Regulatory filing | Multiple CMC sections from different vendors — risk of missing information | Single, coherent CMC section | Lower filing risk, fewer queries |
| Intellectual property | Molecule shared with 3+ vendors — higher IP exposure | Single confidentiality agreement | Stronger IP protection |
| Cost | Higher due to duplicate QA/QC, shipping, and contract overhead | Lower total cost — bundled services | Better budget allocation |
Summary: A pre-selection checklist for your PDC CRO
Before signing with any CRO, verify the following with concrete evidence:
1. Has the CRO successfully developed ≥3 PDC programs from discovery to Phase I with a similar payload class?
2. Do they offer in-house linker libraries (>100 linkers) and custom linker synthesis capabilities?
3. Can they perform conjugation optimisation using DoE and provide full characterisation, including DPR, aggregation, and free payload, for each batch?
4. Do they have high-containment facilities for cytotoxic payloads, if applicable?
5. Have they filed ≥1 IND/CTA for a PDC, and what was the regulatory outcome?
6. Can they provide integrated stability programmes under ICH conditions with proven shelf-life data?
Final recommendation: If a CRO answers “no” to any of the first three questions, look elsewhere. The ideal partner is not the one with the most advanced peptide synthesis, but the one that demonstrates end-to-end integration and regulatory foresight because these are the factors that ultimately determine clinical success.
How does ChemExpress address the PDC development challenges described above?
ChemExpress offers a fully integrated PDC development platform covering:
• Custom peptide synthesis, sequence optimisation, and cyclic peptide engineering
• Advanced linker design and development
• Payload synthesis and manufacturing support
• Conjugation process development and optimization
• Analytical characterization and quality control
• Process scale-up and manufacturing support
• Regulatory and CMC documentation assistance
Explore related capabilities: ADC Linker Development | ADC Payload Development | Bioconjugation Services | ADC Manufacturing | Quality & Compliance
What emerging trends should influence your partner selection?
The PDC landscape continues to evolve rapidly. Researchers are exploring novel targeting peptides, next-generation payloads, multifunctional linker systems, and innovative conjugation technologies to expand therapeutic applications beyond oncology. Advances in peptide engineering are also enabling the development of more selective and durable therapeutics with improved tissue penetration and pharmacological profiles.
As clinical pipelines continue to expand, development programs will increasingly require integrated solutions that combine discovery expertise, manufacturing excellence, and regulatory support within a single development framework.
Conclusion
Successful peptide drug conjugate development requires far more than peptide synthesis alone. The complexity of modern PDCs demands expertise across peptide engineering, linker technology, payload development, conjugation chemistry, analytical characterization, manufacturing, and regulatory support.
Organizations evaluating development partners should prioritize integrated capabilities that can support the entire PDC lifecycle. By leveraging a comprehensive platform that combines scientific expertise with scalable development and manufacturing infrastructure, drug developers can accelerate innovation and advance promising PDC candidates toward clinical success.